Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
October 5, 2023NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chief Scientist of NRx...
-
October 2, 2023
Allows initiation of the NRX-101 commercial development to treat Chronic Pain Company plans to seek Fast Track and Breakthrough Therapy Designations from FDA while awaiting near-term results of...
-
September 20, 2023
Focus on implications of the recent Data Sharing Agreement relating to a landmark trial of Ketamine in the treatment of Suicidal Depression NMDA antagonist highly effective in Bipolar subgroup...
-
September 18, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr.
-
September 15, 2023
Ketamine, an NMDA blocker, was highly effective in Bipolar subgroup (p<0.001) NRx plans to present the data to FDA with a goal of identifying a path to an NDA RADNOR, Pa., Sept. 15, 2023...
Click here to view our corporate presentation or on the image below
 |
